Moving from a scientific to a business-oriented outlook is an inherent challenge of the Pharma market. This is why many blockbuster drugs of Big Pharma Players have been licensed from small Pharma players or academia centers of research universities, as the former entities have a great sense of business. Correctly called other’s science, these drugs receive a platform to perform exceptionally well in the market. Still, such licensing processes possess inherent challenges.
Here comes our game-modifying role, where we assist either of the entities to find the other through our proprietary licensing service offering. Designed in such a way that we see- every time- the best strategic licensing partner for our clients. (Having a specialty in all therapeutic areas and networks globally, we are expertly positioned to provide the best consulting advice.